Posted On: 12 MAY 2021, Delhi
| India’s Active Caseload Declines for the Second Consecutive dayWHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of ConcernGovernment to ramp up availability of Amphotericin B – to fight Mucormycosis |
#Unite2FightCorona
#IndiaFightsCorona
PRESS INFORMATION BUREAU
MINISTRY OF INFORMATION AND BROADCASTING
GOVERNMENT OF INDIA
India’s Active Caseload Declines for the Second Consecutive day
- New Recoveries outnumber Daily New COVID Cases for the Second Consecutive day
- India’s Cumulative Vaccination Coverage exceeds 17.5 Crore
- More than 30 lakh beneficiaries of age group 18-44 Vaccinated so far
- The National Recovery Rate is 83.04%.
- The National Mortality Rate currently stands at 1.09%.
For details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717870
WHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern
This is to clarify that WHO has not associated the term “Indian Variant” with the B.1.617 variant of the coronavirus in its 32 page document.
For Details :https://pib.gov.in/PressReleasePage.aspx?PRID=1717876
Ministry of Power takes proactive measures to ensure 24×7 power supply to Oxygen Power Plants in the Country
In view of the pan India impact of the second wave of corona virus pandemic across the country and the manifold rise in oxygen demand for both medical facilities and for home treatment of patients , the Ministry of Power has undertaken a number of pro-active preventive and remedial measures to ensure that there is uninterrupted power supply to Oxygen Plants by the State Utilities
For Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717861
Government take steps to ramp up availability of Amphotericin B – to fight Mucormycosis
A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically.
For Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717864
PIB FACT CHECK
